JP2024523525A - Glp-1受容体アゴニストならびにその組成物および使用 - Google Patents
Glp-1受容体アゴニストならびにその組成物および使用 Download PDFInfo
- Publication number
- JP2024523525A JP2024523525A JP2023579274A JP2023579274A JP2024523525A JP 2024523525 A JP2024523525 A JP 2024523525A JP 2023579274 A JP2023579274 A JP 2023579274A JP 2023579274 A JP2023579274 A JP 2023579274A JP 2024523525 A JP2024523525 A JP 2024523525A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mmol
- ring
- group
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110702643 | 2021-06-24 | ||
| CN202110702643.0 | 2021-06-24 | ||
| PCT/CN2022/100685 WO2022268152A1 (zh) | 2021-06-24 | 2022-06-23 | Glp-1受体激动剂及其组合物和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523525A true JP2024523525A (ja) | 2024-06-28 |
| JP2024523525A5 JP2024523525A5 (cg-RX-API-DMAC7.html) | 2025-06-27 |
Family
ID=84544137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579274A Pending JP2024523525A (ja) | 2021-06-24 | 2022-06-23 | Glp-1受容体アゴニストならびにその組成物および使用 |
Country Status (18)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026049510A1 (en) * | 2024-08-28 | 2026-03-05 | Yuhan Corporation | Thienoimidazole compounds having glp-1 receptor agonist activity, methods for preparing same, and medical uses thereof |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20220178A (es) | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| LT4271672T (lt) | 2021-04-21 | 2026-03-10 | Gilead Sciences, Inc. | Karboksibenzimidazolo junginiai, moduliuojantys glp-1r |
| KR20240053617A (ko) | 2021-08-30 | 2024-04-24 | 민드랭크 에이아이 리미티드 | Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물 |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| CN119907794A (zh) | 2022-09-22 | 2025-04-29 | 盐野义制药株式会社 | 具有glp-1受体激动剂作用的稠环化合物 |
| AU2023394509A1 (en) * | 2022-12-13 | 2025-07-10 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Salt-type glp-1 receptor agonist, crystal form thereof, preparation method therefor, pharmaceutical composition thereof, and use thereof |
| JP2026501161A (ja) * | 2022-12-13 | 2026-01-14 | 杭州中美華東製薬有限公司 | Glp-1受容体作動薬の新規結晶形、その製造方法、その医薬組成物およびその使用 |
| CN118496200A (zh) * | 2023-02-14 | 2024-08-16 | 成都康弘药业集团股份有限公司 | 吲唑啉酮类化合物及其制备方法和用途 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| CN121866253A (zh) | 2023-07-04 | 2026-04-14 | 杭州中美华东制药有限公司 | 一种glp1r激动剂及其中间体的制备方法 |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| TW202612693A (zh) * | 2024-06-05 | 2026-04-01 | 大陸商杭州中美華東製藥有限公司 | Glp-1受體激動劑的口服藥物組合物及其製備方法 |
| TW202615019A (zh) * | 2024-09-05 | 2026-04-16 | 大陸商杭州中美華東製藥有限公司 | Glp-1r激動劑與恩格列淨的藥物組合物及用途 |
| CN119837849B (zh) * | 2025-02-10 | 2025-06-13 | 中国科学院北京基因组研究所(国家生物信息中心) | 蜡菊素在制备缓解和治疗受试者细胞红系分化障碍的药物中的应用 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020511411A (ja) * | 2016-12-16 | 2020-04-16 | ファイザー・インク | Glp−1受容体アゴニストおよびその使用 |
| WO2020103815A1 (en) * | 2018-11-22 | 2020-05-28 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| WO2020207474A1 (en) * | 2019-04-12 | 2020-10-15 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| WO2021018023A1 (zh) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| WO2021081207A1 (en) * | 2019-10-25 | 2021-04-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022068772A1 (zh) * | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| WO2022109182A1 (en) * | 2020-11-20 | 2022-05-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| JP2023515404A (ja) * | 2020-02-13 | 2023-04-13 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
| JP2024514010A (ja) * | 2021-04-21 | 2024-03-27 | ギリアード サイエンシーズ, インコーポレイテッド | カルボキシ-ベンズイミダゾールglp-1r調節化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA018225B1 (ru) | 2008-03-07 | 2013-06-28 | Транстек Фарма, Инк. | Соединения оксадиазоантрацена для лечения диабета |
| MX2011010347A (es) | 2009-03-30 | 2011-11-29 | Transtech Pharma Inc | Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos. |
| US10723699B2 (en) | 2015-11-04 | 2020-07-28 | Hyundai Pharm Co., Ltd. | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| KR101910586B1 (ko) | 2017-03-03 | 2018-10-23 | 한국화학연구원 | 헤테로아릴이 치환된 2-페닐이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 GLP-1 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
-
2022
- 2022-06-23 CN CN202280018027.6A patent/CN117098758A/zh active Pending
- 2022-06-23 AU AU2022300055A patent/AU2022300055A1/en active Pending
- 2022-06-23 PE PE2023003275A patent/PE20241794A1/es unknown
- 2022-06-23 WO PCT/CN2022/100685 patent/WO2022268152A1/zh not_active Ceased
- 2022-06-23 KR KR1020247001274A patent/KR20240024910A/ko active Pending
- 2022-06-23 TW TW111123462A patent/TW202317553A/zh unknown
- 2022-06-23 CR CR20230611A patent/CR20230611A/es unknown
- 2022-06-23 IL IL309235A patent/IL309235A/en unknown
- 2022-06-23 MX MX2023014985A patent/MX2023014985A/es unknown
- 2022-06-23 JP JP2023579274A patent/JP2024523525A/ja active Pending
- 2022-06-23 CN CN202311318579.1A patent/CN117362283B/zh active Active
- 2022-06-23 EP EP22827644.0A patent/EP4361145A4/en active Pending
- 2022-06-23 CA CA3219984A patent/CA3219984A1/en active Pending
-
2023
- 2023-09-13 US US18/367,517 patent/US11981666B2/en active Active
- 2023-12-14 DO DO2023000275A patent/DOP2023000275A/es unknown
- 2023-12-18 CO CONC2023/0017726A patent/CO2023017726A2/es unknown
- 2023-12-19 EC ECSENADI202395307A patent/ECSP23095307A/es unknown
- 2023-12-19 CL CL2023003794A patent/CL2023003794A1/es unknown
-
2024
- 2024-01-23 ZA ZA2024/00786A patent/ZA202400786B/en unknown
- 2024-03-22 US US18/613,714 patent/US20240360110A1/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020511411A (ja) * | 2016-12-16 | 2020-04-16 | ファイザー・インク | Glp−1受容体アゴニストおよびその使用 |
| WO2020103815A1 (en) * | 2018-11-22 | 2020-05-28 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| WO2020207474A1 (en) * | 2019-04-12 | 2020-10-15 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| WO2021018023A1 (zh) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| WO2021081207A1 (en) * | 2019-10-25 | 2021-04-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| JP2023515404A (ja) * | 2020-02-13 | 2023-04-13 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
| WO2022068772A1 (zh) * | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| WO2022109182A1 (en) * | 2020-11-20 | 2022-05-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| JP2024514010A (ja) * | 2021-04-21 | 2024-03-27 | ギリアード サイエンシーズ, インコーポレイテッド | カルボキシ-ベンズイミダゾールglp-1r調節化合物 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026049510A1 (en) * | 2024-08-28 | 2026-03-05 | Yuhan Corporation | Thienoimidazole compounds having glp-1 receptor agonist activity, methods for preparing same, and medical uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| PE20241794A1 (es) | 2024-09-06 |
| WO2022268152A1 (zh) | 2022-12-29 |
| TW202317553A (zh) | 2023-05-01 |
| CN117362283A (zh) | 2024-01-09 |
| CN117098758A (zh) | 2023-11-21 |
| EP4361145A1 (en) | 2024-05-01 |
| ZA202400786B (en) | 2024-10-30 |
| CA3219984A1 (en) | 2022-12-29 |
| CL2023003794A1 (es) | 2024-05-24 |
| MX2023014985A (es) | 2024-02-14 |
| DOP2023000275A (es) | 2024-02-15 |
| IL309235A (en) | 2024-02-01 |
| ECSP23095307A (es) | 2024-01-31 |
| KR20240024910A (ko) | 2024-02-26 |
| CO2023017726A2 (es) | 2024-02-15 |
| CR20230611A (es) | 2024-02-19 |
| US11981666B2 (en) | 2024-05-14 |
| CN117362283B (zh) | 2024-07-09 |
| US20240360110A1 (en) | 2024-10-31 |
| EP4361145A4 (en) | 2025-05-21 |
| AU2022300055A1 (en) | 2024-01-18 |
| US20240116906A1 (en) | 2024-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117362283B (zh) | Glp-1受体激动剂及其组合物和用途 | |
| EP4227299A1 (en) | Benzimidazolone glp-1 receptor agonist and use thereof | |
| CN113853371B (zh) | Glp-1r激动剂及其用途 | |
| WO2022199458A1 (zh) | 噻吩类glp-1受体激动剂及其用途 | |
| CN114907351A (zh) | 三环类glp-1受体激动剂及其用途 | |
| CN114867720A (zh) | 杂芳基类衍生物及其制备方法和用途 | |
| WO2020147739A1 (zh) | 溶血磷脂酸受体拮抗剂及其制备方法 | |
| TWI719974B (zh) | 9員縮合環衍生物 | |
| CN114478497A (zh) | 芳基烷基酸类glp-1受体激动剂及其用途 | |
| TW201211053A (en) | Spiro compound and drug for activating adiponectin receptor | |
| CN113278013B (zh) | 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用 | |
| WO2025176130A1 (zh) | 一种含吡唑并环类化合物、其药物组合物及其用途 | |
| EP4587429A1 (en) | Substituted oxoisoindolinyl piperidine-2,6-dione compounds | |
| WO2025112584A1 (zh) | 一种含硒元素类化合物及其用途 | |
| TW202542146A (zh) | 靶向glp-1受體的化合物以及其用途 | |
| CN117586240A (zh) | Glp-1受体激动剂及其用途 | |
| CN121362177A (zh) | Apj激动剂 | |
| HK40099392A (en) | Glp-1 receptor agonist and composition and use thereof | |
| HK40099392B (en) | Glp-1 receptor agonist and composition and use thereof | |
| WO2022078356A1 (zh) | 杂芳环类AhR抑制剂 | |
| EA049148B1 (ru) | Агонист рецептора glp-1, его композиция и его применение | |
| KR20250128310A (ko) | Hur 조절 화합물 (elavl1) | |
| HK40041774A (en) | Lysophosphatidic acid receptor antagonists and preparation method therefor | |
| WO2024153237A1 (zh) | 一种igf-1r酪氨酸激酶抑制剂、药物组合物及其用途 | |
| CN113004252A (zh) | 一种芳基并咪唑类衍生物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250619 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250619 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260310 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260610 |